The board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that the Company has announced clinical results of in-house novel KRAS G12C inhibitor Glecirasib (JAB-21822) monotherapy and in combination with cetuximab to treat KRAS G12C mutant advanced colorectal cancer(CRC) in Second JCA-AACR Precision Cancer Medicine International Conference. In the monotherapy study, overall response rate (ORR) is 33.3% (11/33), disease control rate (DCR) is 90.9% (30/33), mPFS (median progression-free survival) is 6.9 months. In a clinical trial of Glecirasib with cetuximab, ORR is 62.8% (27/43), DCR is 93% (40/43), mPFS has not reached before the May 23, 2023 data cutoff date.

In terms of safety, the majority of treatment-related adverse events (TRAEs) in monotherapies and combinations are grades 1-2. Colorectal cancer is the second most common cancer in China, with about 550,000 new cases per year, of which about 3% of colorectal cancer patients have KRAS G12C mutation. Patients with KRAS G12C mutation are insensitive to existing standard chemotherapies and targeted therapies, have rapid disease progression, short survival, and they have high unmet clinical treatment needs. Glecirasib has the potential to bring effective and less toxic treatment option for patients.